HIV-1 RNA at 24 and 48 weeks follow-up after dual antiretroviral therapy initiation (intention-to-treat analysis)
| N (%) | All patients n=51, % (95% CI) | HIV-1 RNA <50 copies/mL* n=37, % (95% CI) | HIV-1 RNA ≥50 copies/mL* n=14, % (95% CI) | |
| 24 weeks | <50 copies/mL | 42, 82.4% (71.9% to 92.9%) | 34, 91.9% (83.1% to 100.0%) | 8, 57.1% (31.2% to 83.0%) |
| ≥50 copies/mL | 2†, 3.9% (0.0% to 9.2%) | 1†, 2.7% (0.0% to 7.9%) | 1, 7.1% (0.0% to 15.4%) | |
| Discontinuations or loss to follow-up | 7, 13.7% (4.3% to 23.1%) | 2, 5.4% (0.0% to 12.7%) | 5, 35.7% (20.3% to 51.1%) | |
| N (%) | All patients n=51, % (95% CI) | HIV-1 RNA <50 copies/mL* n=37, % (95% CI) | HIV-1 RNA ≥50 copies/mL* n=14, % (95% CI) | |
| 48 weeks | <50 copies/mL | 38, 74.5% (62.5% to 86.5%) | 31, 83.8% (71.9% to 95.7%) | 7, 50.0% (33.9% to 66.1%) |
| ≥50 copies/mL | 2†, 3.9% (0.0% to 9.2%) | 2†, 5.4% (0.0% to 12.7%) | 0 | |
| Discontinuations or loss to follow-up | 11, 21.6% (10.3% to 32.9%) | 4, 10.8% (0.8% to 20.8%) | 7, 50.0% (33.9% to 66.1%) | |
*At baseline.
†Discontinued due to virological failure before 24 weeks follow-up, 1 patient.